Table 3 Comparison of the baseline characteristics of the SC combined with TLC group and TLC group before the intervention.

From: Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B

 

SC combined with TLC group

TLC group

P

Age, years

42.7 ± 8.9

45.49 ± 9.6

0.004

Male patients, n (%)

108 (93.9)

125 (80.6)

0.002

BMI, kg/m2

25.21 ± 3.2

24.2 ± 3.1

0.629

Waist circumference, cm

87.38 ± 16.1

85.2 ± 7.4

0.216

Hip circumference, cm

96.74 ± 5.6

95.12 ± 5.4

0.389

ALT, U/L

46 (32–68)

34 (23–47)

 < 0.001

AST, U/L

37 (27–53)

30 (24–39)

0.001

Fasting glucose, mmol/L

5.67 ± 1.3

5.90 ± 1.9

0.881

TG, mmol/L

1.76 ± 1.2

1.55 ± 1.0

0.417

Cholesterol, mmol/L

4.18 ± 1.2

4.17 ± 0.8

0.836

HDL-C, mmol/L

1.40 ± 1.2

1.21 ± 0.4

0.546

LDL-C, mmol/L

2.43 ± 0.8

2.42 ± 0.73

0.983

ALB, g/L

45.83 ± 5.3

45.30 ± 4.1

0.281

GLB, g/L

31.37 ± 9.9

31.2 ± 6.4

0.127

TB, μmol/L

22.8 ± 38.0

19.17 ± 13.4

0.297

DB, μmol/L

9.3 ± 26.8

6.37 ± 7.1

0.815

GGT, U/L

32 (19–58)

28 (17–46)

0.117

ALP, U/L

78 (62–101)

75 (65–99)

0.811

Platelet × 109/L

118 (81–169)

108 (72–168)

0.678

Undetectable HBV DNA, n (%)

90 (78.3)

122 (78.7)

0.929

HBeAg-negative, n (%)

79 (68.7)

108 (69.7)

0.469

NAs treatment, n (%)

70 (60.9)

101 (65.2)

0.449

LSM, kPa

12.31 ± 8.0

11.48 ± 8.2

0.279

CAP, dB/m

282.11 ± 37.30

272.43 ± 28.20

0.115

  1. BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, TB total bilirubin, DB direct bilirubin, TG triacylglycerol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, GGT gamma glutamyltransferase, ALP alkaline phosphatase, LSM liver stiffness measurement, CAP controlled attenuation parameter.
Back to article page